10-K: Adagio Medical Holdings Reports Fiscal Year 2024 Results, Outlines Strategic Realignment

Adagio Medical Holdings files its 10-K, detailing 2024 financials, a strategic shift towards ventricular tachycardia treatment, and ongoing efforts to secure regulatory approvals.

Summary

• Adagio Medical Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company is focused on developing and commercializing products for cardiac arrhythmias, particularly ventricular tachycardia (VT), using its Ultra-Low Temperature Cryoablation (ULTC) technology.
• Adagio's VT Cryoablation System has received CE Mark approval in Europe, and the company is pursuing FDA approval in the U.S. with its FULCRUM-VT clinical trial.
• The company estimates the global market for EP ablation catheters to be approximately $4.5 billion.
• Adagio incurred net losses of $75.0 million in 2024 and $36.6 million in 2023.
• As of December 31, 2024, Adagio had cash of $20.6 million and an accumulated deficit of $70.6 million.
• A strategic restructuring was announced in February 2025 to prioritize the FULCRUM-VT trial and a new product design optimization program.
• The company is actively pursuing strategies to mitigate going concern risks, including a recent restructuring of its business.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as CE Mark approval and ongoing clinical trials, the significant net losses, accumulated deficit, and going concern uncertainty weigh heavily on the sentiment.

Positives

• The company's VT Cryoablation System has received CE Mark approval in Europe.
• The FULCRUM-VT clinical trial is currently enrolling patients across 20 centers in the U.S. and Canada.
• The company is developing Pulsed Field Cryoablation (PFCA) technology, which combines ULTC and Pulsed Field Ablation.
• Adagio received a Class B designation with full reimbursement for the FULCRUM-VT trial from the U.S. Center for Medicare and Medicaid Services (CMS).

Negatives

• The company has incurred net losses in every period to date and expects to continue to incur significant losses.
• The company's financial conditions raise substantial doubt about its ability to continue as a going concern.
• The company is not in compliance with Nasdaq's audit committee requirements.
• The company has identified material weaknesses in its internal controls over financial reporting.

Risks

• The company's failure to recognize the anticipated benefits of the Business Combination.
• The company's lack of operating history and revenues.
• The company's dependence on its ability to accelerate the commercialization of its products.
• The highly competitive nature of the life sciences technology market.
• The company's potential inability to establish manufacturing capacity in a timely and cost-effective manner.
• The company's potential failure to raise additional capital to fund its development and commercialization plans.
• The risks related to unfavorable U.S. or global economic conditions.
• The potential loss of one or more of the company's executive officers and other key employees.
• The company's potential failure to comply with federal, state, and local laws and regulations.
• The company's potential inability to maintain the listing of its common stock on the Nasdaq Capital Market.

Future Outlook

The company anticipates continuing to incur operating losses and negative cash flows for at least the next several years and expects to submit the results of the FULCRUM-VT trial to support FDA approval of its VT Cryoablation System in the second half of 2025.

Industry Context

The company operates in the electrophysiology (EP) market, which includes tools for diagnosing and treating abnormal heart rhythms. The global market for EP ablation catheters is estimated at $4.5 billion.

Comparison to Industry Standards

• The major players in the cardiac EP and advanced ablation catheter markets are Biosense Webster (a division of Johnson & Johnson), Abbott, Medtronic, and Boston Scientific.
• VT ablations are predominantly performed using point-by-point RF ablation catheter technology, with RF catheters by Biosense Webster and Abbott Electrophysiology being commonly used.
• Thermedical, Inc. is conducting an upcoming 130-patient multicenter U.S. FDA Trial, which is expected to conclude in 2027.

Management Changes

Corporate Governance

Related Party Transactions

• The company incurred expenses for finance and accounting services and other general and administrative support services to Fjord Ventures, LLC, a company owned and operated by the company's CEO.
• The company sub-leased office and manufacturing space in Laguna Hills, California from Fjord Ventures, LLC.
• The company issued a convertible promissory note to Fjordinvest, LLC, a company owned and operated by the company's CEO.
• The company issued Convertible Securities Notes to Perceptive PIPE Investor, the controlling party of the company, in exchange for Perceptive PIPE Investor's investment in Legacy Adagio in the form of the February 2024 Convertible Notes.
• The company issued shares of the company's Common Stock and Base Warrants to Perceptive PIPE Investor, the controlling party of the company, in exchange for Perceptive PIPE Investor's investment in Legacy Adagio in the form of Bridge Financing Notes.
• The company issued shares of the company's Common Stock and Base Warrants to Perceptive PIPE Investor, the controlling party of the company, in exchange for Perceptive PIPE Investor's additional cash investment in the company.

Stakeholder Impact

• Shareholders may experience dilution due to potential future equity issuances.
• Employees may be affected by the strategic restructuring and workforce reduction.
• Customers may experience a pause in the European launch of the vCLAS catheter.
• Suppliers may be affected by the company's strategic restructuring and realignment of resources.

Next Steps

• Complete the FULCRUM-VT pivotal clinical trial and submit the results to the FDA.
• Continue to develop and commercialize its Pulsed Field Cryoablation (PFCA) technology.
• Pursue opportunities for facility expansion and transfer of manufacturing operations to qualified third-party suppliers.
• Negotiate other cash equity or debt financing in the short-term.
• Execute cost-cutting measures to manage cash burn.

Key Dates

Keywords

cryoablation, ventricular tachycardia, medical device, ablation, arrhythmias, FULCRUM-VT, vCLAS, ULTC, PFCA, Adagio Medical